Claims

1. Use of an activin receptor antagonist in the manufacture of a medicament for the treatment of obesity or overweight condition in a human subject, wherein the activin receptor antagonist is an anti-ActRII receptor antibody;
wherein the anti-ActRII receptor antibody comprises a light chain of SEQ ID NO: 7 or a sequence having 95% identity with SEQ ID NO: 7; and a heavy chain of SEQ ID NO: 9 or a sequence having 95% identity with SEQ ID NO: 9; and
wherein the anti-ActRII receptor antibody comprises a heavy chain variable domain comprising the CDR1 of SEQ ID NO: 1, CDR2 of SEQ ID NO: 2 and CDR3 of SEQ ID NO: 3; and a light chain variable domain comprising theCDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

2. Use of an activin receptor antagonist according to claim 1, wherein said subject has a BMI ≥ 30 kg/m^2 or a BMI ≥ 25 kg/m^2 to < 30 kg/m^2.

3. Use of an activin receptor antagonist according to claim 1 or 2, wherein the treatment comprises treating an obesity-related or overweight confition-related comorbidity selected from the group consisting of type 2 diabetes, glucose intolerance, prediabetes, insulin resistance, high triglycerides, physical impairment, osteoporosis, renal disease, obstructive sleep apnea, sexual hormones impairment, endocrine reproductive disorders such as polycystic ovary syndrome or male hypogonadism, osteoarthritis, gastrointestinal cancers, dyslipidaemia, hypertension, heart failure, coronary heart disease, stroke, gallstones, and altered gonadal hormone profile.

4. Use of an activin receptor antagonist according to any of claims 1-3 wherein the treatment comprises the treatment, reduction or prevention of type II diabetes.

5. Use of an activin receptor antagonist in the manufacture of a medicament for improving glycemic control in a human subject suffering from type II diabetes, wherein the activin receptor antagonist is an anti-ActRII receptor antibody;
wherein the anti-ActRII receptor antibody comprises a light chain of SEQ ID NO: 7 or a sequence having 95% identity with SEQ ID NO: 7; and a heavy chain of SEQ ID NO: 9 or a sequence having 95% identity with SEQ ID NO: 9; and
wherein the anti-ActRII receptor antibody comprises a heavy chain variable domain comprising the CDR1 of SEQ ID NO: 1, CDR2 of SEQ ID NO: 2 and CDR3 of SEQ ID NO: 3; and a light chain variable domain comprising theCDR1 of SEQ ID NO: 4, CDR2 of SEQ ID NO: 5 and CDR3 of SEQ ID NO: 6.

6. Use of an activin receptor antagonist according to claim 5, wherein improving glycemic control is achieved by improving insulin sensitivity.

7. Use of an activin receptor antagonist according to claims 5 or 6, wherein the subject is suffering from obesity or overweight condition.

8. Use of an activin receptor antagonist according to claim 7 wherein the DTSQ score (Diabetes treatment satisfaction questionnaire score, or IWQOL/IWQOL-lite (Impact of Weight on Quality of Life) score or other patient related outcome (PRO) related to obesity and/or diabetes are improved.

9. Use of an activin receptor antagonist according to any one of the claims 1-8 wherein the anti-ActRII receptor antibody is bimagrumab.

10. Use of an activin receptor antagonist according to claim 9, wherein the anti- ActRII receptor antibody is administered at a dose of 3 mg/kg or 10 mg/kg.

11. Use of an activin receptor antagonist according to claim 10, wherein the anti-ActRII receptor antibody is administered every 4 weeks.